776 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B Uptrend
Article Searches
Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates http://www.zacks.com/stock/news/411257/aduro-adro-q1-earnings-and-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-411257 May 08, 2019 - Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.
What's in the Cards for Nektar (NKTR) This Earnings Season? http://www.zacks.com/stock/news/410186/whats-in-the-cards-for-nektar-nktr-this-earnings-season?cid=CS-ZC-FT-410186 May 07, 2019 - The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss http://www.zacks.com/stock/news/409993/bauschs-bhc-q1-earnings-beat-estimates-revenues-miss?cid=CS-ZC-FT-409993 May 07, 2019 - Bausch (BHC) Q1 earnings surpass estimates, while revenues miss the same. The increase in guidance was impressive.
BMY: Barclays ups to Overweight http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190503064059 May 03, 2019 - Barclays issues rating change for BMY
Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1 http://www.zacks.com/stock/news/407891/exelixis-exel-earnings-revenues-beat-estimates-in-q1?cid=CS-ZC-FT-407891 May 02, 2019 - Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.
Top Research Reports for ExxonMobil, Morgan Stanley & Bristol-Myers http://www.zacks.com/research-daily/406648/top-research-reports-for-exxonmobil-morgan-stanley-bristol-myers?cid=CS-ZC-FT-406648 May 01, 2019 - Top Research Reports for ExxonMobil, Morgan Stanley & Bristol-Myers
3 Stocks Peter Lynch Would Love https://www.fool.com/investing/2019/04/29/3-stocks-peter-lynch-would-love.aspx?source=iedfolrf0000001 Apr 29, 2019 - They could be big winners for patient investors.
5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates http://www.zacks.com/stock/news/405274/5-drug-biotech-stocks-poised-to-beat-q1-earnings-estimates?cid=CS-ZC-FT-405274 Apr 28, 2019 - So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.
Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales http://www.zacks.com/stock/news/404541/celgene-celg-q1-earnings-beat-estimates-on-revlimid-sales?cid=CS-ZC-FT-404541 Apr 26, 2019 - Celgene (CELG) beats on earnings and sales in the first quarter of 2019.
Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4256820-bristol-myers-squibb-company-bmy-ceo-giovanni-caforio-q1-2019-results-earnings-call?source=feed_sector_healthcare Apr 25, 2019 - Bristol-Myers Squibb Company (NYSE:BMY) Q1 2019 Earnings Conference Call April 25, 2019 10:30 AM ET Company Participants John Elicker - Senior Vice President, Public Affairs & Investor Relations G

Pages: 1234567...78

<Page 2>